Gemcitabine plus docetaxel takes first and second place

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1648, 2008-01, pp. : 14-14

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Gemcitabine plus docetaxel `has moderate activity' in advanced pancreatic cancer

Inpharma, Vol. 1, Iss. 1281, 2001-01 ,pp. : 15-15

Adis International

Access to resources Recommend Favorite

Docetaxel plus gemcitabine shows antitumour efficacy in patients with advanced NSCLC

Inpharma, Vol. 1, Iss. 1280, 2001-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite

Irinotecan plus docetaxel a first-line option for NSCLC

Inpharma, Vol. 1, Iss. 1470, 2005-01 ,pp. : 15-16

Adis International

Access to resources Recommend Favorite

Docetaxel/gemcitabine: First report of muscular disorders: case report

Reactions Weekly, Vol. 1, Iss. 1052, 2005-01 ,pp. : 8-9

Adis International

Access to resources Recommend Favorite

Phase I/II trial of gemcitabine plus docetaxel in advanced non small cell lung cancer (NSCLC)

By Israel Valerie Tagawa Scott Snyder Terry Jeffers Susan Raghavan Derek

Investigational New Drugs, Vol. 22, Iss. 3, 2004-08 ,pp. : 291-297

Springer Publishing Company

Access to resources Recommend Favorite